Coherus Oncology, Inc. (CHRS) stock
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3038% below fair value
$0.53−0.01 (-2.41%)
Close on Nov 13, 2026Market cap $81.19MP/E –Yield –
Coherus Oncology enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Coherus Oncology's enterprise value was -$15.32M on Nov 11, 2026, against -$33.82M a year earlier. Over the last 5 years it ranged from -$103.08M to $753.56M, with a median of $101.33M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$15.32M | – |
| 2025 | Dec 31, 2025 | -$26.85M | -144.0% |
| 2024 | Dec 31, 2024 | $61.04M | -73.7% |
| 2023 | Dec 29, 2023 | $232.27M | -29.4% |
| 2022 | Dec 30, 2022 | $329.14M | -56.3% |
| 2021 | Dec 31, 2021 | $753.56M | -16.9% |
| 2020 | Dec 31, 2020 | $907.28M | -22.1% |
| 2019 | Dec 31, 2019 | $1.16B | +159.2% |
| 2018 | Dec 31, 2018 | $449.18M | +57.5% |
| 2017 | Dec 29, 2017 | $285.17M | -72.5% |
| 2016 | Dec 30, 2016 | $1.04B | +70.3% |
| 2015 | Dec 31, 2015 | $609.38M | – |
| 2014 | Dec 31, 2014 | -$25.56M | – |
See a number that looks wrong?